Indicated for adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.1,2
The first and only self-administered once-monthly (20 mg), subcutaneous (SC), B-cell therapy for RMS
• KESIMPTA is intended for patient self-administration with initial guidance from an HCP
Following the Real world experience of KESIMPTA webinar on the 13th of December 2021, check out these case examples from Noreen Barker and Dr Wallace Brownlee and lookout for more content to follow soon.
Watch Dr Wallace Brownlee, Consultant Neurologist and Clinical Lead for the multiple sclerosis service at the National Hospital for Neurology and Neurosurgery, discuss the diagnostic investigations of a patient who presented with right optic neuritis with incomplete recovery and no previous history of neurological symptoms.
Prescribing information can be found at the end of the video.
Watch Noreen Barker, MS Consultant Nurse talk about her experience with treatment initiation and monitoring through KesimptaConnect.
Ofatumumab is recommended as an option for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features. This is only if the company provides ofatumumab according to the commercial arrangement.
This recommendation is not intended to affect treatment with ofatumumab that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.
Advice: following a full submission
Two phase III studies demonstrated superiority of ofatumumab in reducing annualised relapse rate when compared with another disease-modifying treatment (DMT) in adult patients with RMS.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.
ARR, annualised relapse rate; CDW, confirmed disability worsening; CI, confidence interval; DMT, disease-modifying treatment; Gd+, gadolinium enhancing; HCP, healthcare professional; MS, multiple sclerosis; NEDA, no evidence of disease activity; NICE, National Institute of Health and Care Excellence; PAS, patient access scheme; RMS, relapsing forms of multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SC, subcutaneous; SMC, Scottish Medicines Consortium; SmPC, Summary of Product Characteristics.
*Primary endpoint: relative reduction in adjusted ARR vs teriflunomide of 51% (0.11 vs 0.22) in ASCLEPIOS I and 59% (0.10 vs 0.25) in ASCLEPIOS II.1,2
†Post hoc analysis of KESIMPTA patients who achieved NEDA-3. No conclusions of clinical outcomes can be drawn. Post hoc analysis of ASCLEPIOS I and ASCLEPIOS II studies included all patients from the pivotal trial full analysis set population in the intent-to-treat principle, but patients who discontinued from the study drug prematurely for reasons other than “lack of efficacy” or “death” and had NEDA-3 before early discontinuations were excluded. The analysis occurred within the prespecified time period (i.e. 0–12 months and 12–24 months), and included patients who achieved NEDA-3, defined as no 6-month CDW, confirmed relapse, ≥1 Gd+ T1 lesions, ≥1 T2 lesions, or discontinuation from the study drug due to either lack of efficacy or death.1,2,10 88% (8.8/10 patients) of patients taking KESIMPTA achieved NEDA-3 in Months 12–24.7,8
‡The first injection of KESIMPTA should be performed under the guidance of an appropriately trained healthcare professional. The initial dosing period consists of 20 mg SC doses at Weeks 0, 1 and 2.1,2
§Based on a survey of 80 MS patients and 50 MS nurses. The survey was conducted in two phases – central location pilots (Germany) followed by face-to-face semi-structured in-field interviews across the USA, Germany, France, and Italy. Comparison autoinjector pens included Rebismart®, Rebidose®, Avonex Pen®, Autoject® 2, YpsoMate® and Plegridy Pen®. 84% of participants preferred the Sensoready® autoinjector over other MS disease-modifying therapy autoinjectors.
- KESIMPTA Summary of Product Characteristics. Great Britain: Novartis Pharmaceuticals UK Ltd; April 2021.
- KESIMPTA Summary of Product Characteristics. Novartis Ireland Limited; March 2021.
- Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New Engl J Med. 2020;383:546–557.
- Perrin Ross, A, Besser C, Naval S, et al. Patient and Nurse Preferences for the Sensoready® Autoinjector Pen Versus Other Autoinjectors in Multiple Sclerosis: Results From a Multicenter Survey [Poster P210]. Poster presented at: Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2021; 25–27 February 2021.
- National Institute for Health and Care Excellence (2021). Ofatumumab for treating relapsing multiple sclerosis (NICE guideline 699). Available at: https://www.nice.org.uk/guidance/ta699/resources/ofatumumab-for-treating... [Accessed November 2021].
- Scottish Medicines Consortium (2021). Advice following a full submission: ofatumumab (Kesimpta®) is accepted for restricted use within NHS Scotland. Available at: https://www.scottishmedicines.org.uk/medicines-advice/ofatumumab-kesimpt... [Accessed November 2021].
- Data on file. OMB157 (ofatumumab). Summary of clinical efficacy in relapsing multiple sclerosis. Novartis Pharmaceuticals Corp; East Hanover, NJ. December 2019.
- Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab vs Teriflunomide in Relapsing Multiple Sclerosis: Analysis of No Evidence of Disease Activity (NEDA-3) from ASCLEPIOS I and II Trials [Poster LB62]. Presented at: 6th European Academy of Neurology (EAN) Congress as Virtual Congress; 23–26 May 2020.
- Hauser SL, Bar-Or A, Cohen J, et al. B-cell depletion and efficacy outcomes with ofatumumab: subgroup analysis from the pooled phase 3 ASCLEPIOS I and II trials [Poster P7.1-013]. Presented at: American Academy of Neurology (AAN); 25 April–1 May 2020; Toronto, Canada [cancelled].
- Data on file. OMB157 (ofatumumab). OMB 157G 126.96.36.199. Statistical overview. Novartis Pharmaceuticals Corp; East Hanover, NJ. December 2019.